The National Institute of Neurological Disorders and Stroke (NINDS) awarded SRI International a $9.5-million contract related to the prevention, diagnosis, and treatment of conditions caused by potential and existing chemical agents of terrorism.
SRI will focus on all aspects of preclinical development that can lead to potential therapeutic candidates, including synthetic and natural products and small molecule drugs. SRI will develop analytical methods, perform pharmacology studies, conduct safety evaluations, and formulate and manufacture products for further study. SRI will also prepare therapeutic candidates to enter clinical assessment and evaluate candidate therapies identified in earlier-stage projects supported by the NIH CounterACT program.
This project is part of the CounterACT program, a trans-NIH program to develop improved medical countermeasures for chemical threats that is led by NINDS.